XBiotech Inc. — 2017 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2017; it also reports unaudited fourth-quarter results. XBiotech is a pre-revenue biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies. Its lead candidate, MABp1 (Xilonix), targets IL-1α. The company had no products approved for sale.
Financial results and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $26.4 million | $42.5 million |
| General and administrative expense | $7.6 million | $10.3 million |
| Total operating expenses / operating loss | $34.1 million | $52.8 million |
| Net loss | $33.2 million | $52.8 million |
| Basic and diluted loss per share | $0.95 | $1.63 |
| Cash used in operating activities | $33.6 million | $46.0 million |
| Cash and cash equivalents at year-end | $31.8 million | $34.3 million |
| Working capital at year-end | $30.5 million | $29.0 million |
| Total assets / shareholders’ equity at year-end | $63.0 million / $60.2 million | $67.1 million / $59.1 million |
There was no product revenue, so operating margins are not meaningful. The balance sheet reported $2.8 million in total liabilities, mainly accounts payable and accrued expenses; no debt balance was reported. The company raised approximately $31.6 million net from a March 2017 share offering, plus approximately $1.0 million from an at-the-market share sale and $0.7 million from option exercises. Outstanding shares increased to 35.4 million at year-end from 32.6 million.
Changes versus the prior period
- Net loss narrowed by approximately 37% and operating cash use fell by approximately 27% year over year. R&D expense declined 38%, primarily following completion or discontinuation of Phase III colorectal cancer trials, reduced clinical-trial and manufacturing activity, and a smaller workforce.
- Investing cash outflow fell to $1.4 million from $13.9 million as construction of the new manufacturing facility was substantially completed in 2016. Property and equipment was $29.6 million at year-end 2017.
- Cash declined by $2.6 million during 2017, compared with a $56.7 million decline in 2016, reflecting lower operating and investing outflows and the 2017 equity financing.
- Fourth-quarter 2017 net loss was $7.2 million, or $0.20 per share, versus $16.4 million, or $0.50 per share, in fourth-quarter 2016.
Outlook, developments, and risks
- Lead program setbacks: The FDA-guided global Phase III study in advanced colorectal cancer was discontinued in June 2017 after the second interim analysis did not meet the efficacy/continuation threshold. The EMA maintained its negative opinion on the European marketing application in September 2017; no further procedures were available for that application.
- Other pipeline activity: An investigator-sponsored Phase I pancreatic cancer combination study began in September 2017, planned for 16 patients. In a 20-patient hidradenitis suppurativa study, reported response was 60% with MABp1 versus 10% with placebo (p=0.035). The company also reported Phase I/II results for 514G3, an antibody candidate for S. aureus infections, and continued early research on other infectious-disease candidates.
- Funding and runway: Management said year-end cash was expected to fund operations through one year from the report issuance date. The company expects continued operating losses, has no product revenue, and states it may need substantial additional financing; future funding may be unavailable or dilutive. No specific revenue, earnings, or clinical-development guidance was provided.
- Legal and regulatory matters: A securities class action relating to the 2015 IPO remained stayed while procedural issues were pending; the company said it could not estimate the outcome or financial impact. Another 2017 securities class action was dismissed without prejudice in January 2018. A director’s resignation led to NASDAQ compliance notices; the company reported regaining compliance with certain board and committee requirements after appointing a director, while another audit-committee compliance cure period remained.
- Other key risks: Clinical and regulatory failure, inability to commercialize or obtain reimbursement, competition, patent and third-party IP challenges, dependence on key personnel, and the need to build commercial capabilities. The company reported an accumulated deficit of $216.6 million and losses in every reporting period since inception.
- The audited financial statements received an unqualified opinion from Ernst & Young LLP. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2017; the auditor did not provide an internal-control effectiveness opinion.
Important facts for investors to verify
- Cash runway assumptions and expected spending following the colorectal cancer trial outcomes; assess the timing and terms of any additional financing.
- Whether any new MABp1 studies produce results sufficient to support a viable regulatory strategy, given the terminated U.S. Phase III trial and unsuccessful EMA application.
- Clinical evidence, safety, enrollment progress, and funding requirements for the pancreatic cancer study, 514G3, and other pipeline candidates.
- Status and potential financial exposure of the remaining securities litigation and any outstanding NASDAQ audit-committee compliance requirements.
- Commercial manufacturing facility validation, future operating costs, and the extent of dilution from equity issuance and outstanding stock options.